Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > PP

<< Previous

Bullboard Posts

Next >>

Post by Cotitwoon Sep 16, 2017 7:11pm

145 Views

Post# 26705669

PP

I'm afraid the stock price will be kept lower for a while longer. Once the financing closes we should reach bottom and then start to go up with gynecoligical study results and the start of Head and Neck trials begin

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market